Axsome Therapeutics, Inc. (AXSM) Analyst Forecast
Revenue and earnings estimates published by analysts covering Axsome Therapeutics, Inc. (AXSM), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Axsome Therapeutics, Inc., analysts forecast revenue rising from $635.67T in 2025 to $3642.86T in 2030; the average estimate for 2030 earnings per share is $28.81; with published estimates ranging from $23.34 to $34.64; 16 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Axsome Therapeutics, Inc. (AXSM) forecast — frequently asked questions
What is the analyst price target for Axsome Therapeutics, Inc.?
Analysts covering Axsome Therapeutics, Inc. (AXSM) have a consensus price target of $283.00, 95.8% above the current price of $144.52. Published targets range from $246.00 to $380.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Axsome Therapeutics, Inc.'s earnings?
The average analyst estimate for Axsome Therapeutics, Inc. (AXSM) earnings per share in 2030 is 28.81, with individual estimates between 23.34 and 34.64.
How much revenue is Axsome Therapeutics, Inc. expected to make?
Analysts forecast Axsome Therapeutics, Inc. (AXSM) revenue of $3642.86T in 2030, based on 7 published estimates.
How many analysts cover AXSM?
16 analysts contribute estimates for Axsome Therapeutics, Inc. (AXSM). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.